NCT00701363

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 124 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the efficacy of an extended injection interval schedule of lanreotide Autogel 120 mg in acromegalic subjects who are biochemically controlled on long term treatment with octreotide LAR 10 or 20 mg

Conditions

• Acromegaly

Interventions

Type	Name	Description
DRUG	Lanreotide Autogel 120 mg	120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24

Timeline

• Start date: 2008-10-01
• Primary completion: 2013-03-01
• Completion: 2013-05-01
• First posted: 2008-06-19
• Last updated: 2019-01-29
• Results posted: 2015-12-14

Locations

44 sites across 14 countries: Brazil, Denmark, Finland, France, Greece, Latvia, Netherlands, Norway, Poland, Romania, Russia, Serbia, South Korea, Sweden